Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies

CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia‐related changes. Population pharmacokinetics analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Banerjee, Kamalika, Vasilinin, Grygoriy, Marier, J.F., Gibbons, Jacqueline A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590377/
https://www.ncbi.nlm.nih.gov/pubmed/30566230
http://dx.doi.org/10.1002/jcph.1366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590377/
https://www.ncbi.nlm.nih.gov/pubmed/30566230
http://dx.doi.org/10.1002/jcph.1366

Ejemplares similares